Get started

Healthcare

LKL Massive Accumulation by Bank!!LKL has dropped a lot since most of the supply for Covid-19 was sufficient. People forget about this and jerung2 takes a chance to accumulate their shares little buy little like no one knows. We see massive accumulation happen at the current price level. An early sign of the trend we see in 1H TF where price decrease but the stochastic increase. This indicates buying pressure is high causing Bullish Divergence . Today 16 Mac 2021, buyers show their strength by bringing the price close outside BB+EMA50 indicate the sign of strength (SOS) When the best time to enter? 1. After bullish divergence confirmation (dah terlepas) 2. After MidBB close above EMA50. 3. When MidBB above EMA50 and price retest midBB with oversold stochastic. This is the best chance to enter. Cutloss? If price closes below starting divergence. TP? when you feel enough... But for me... I will close when the price when Daily TF closes below EMA6.
MYX:LKLLong
by ArifHasbollah
5
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken
Exela Technologies Wins $90 Million ContractExela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital transformation efforts for a major US health insurance company and is part of a broader relationship that included over $28 million in revenue in 2020. finance.yahoo.com
X
by AlenCiken
Teladoc Health Ready For A Rally! 🩺TDOC had a massive $133 correction since February 16th. They reported an earnings of -$3.07 which missed estimates of $0.24. Big miss on their earnings accompanied with a correction in the overall market resulted in price landing below $200. The past 4 days TDOC reached a low of $174 and today managed to test the $200 support but failed to get above. I have entered 4/16 $220 calls at close today avg $ of $7.15. Will look to add more TDOC swings on continued show of strength. Over $200/202 TDOC can make a move back to $220 quickly if the market holds up. Chart: HVN: HVN at ~$195 serving as a strong support zone. This is where TDOC can chop around at if it isn’t ready to break $201/202 lvl yet. HVN at $217/220 area serves as first PT. Fib: Fib retracement lvls at $201.5 and $222 serving as good entries/exits. Support/Resistance: Resistance levels roughly at $200,210, 216, and 221 lvls to play off of as well. EMA’s: 20 EMA will be right at 223 on the Daily chart MACD & RSI: both are gearing up for reversals Plan: I entered a smaller position and would like to add heavier on confirmation of a move back to $220 PT. SL: Will be watching $188-$190 lvl to hold as support for SL if we re-trace. Current AH price action has TDOC above $200 but lets see what it does Friday.
NYSE:TDOCLong
by DOpeTrades
Cardinal Health working on breaking through resistanceCardinal health is currently sitting at a resistance level that held from 2000-2013. From 2014-2018 it traded above this resistance level, but in 2018 it dropped back below it. For the last two years, the stock has been trying to break through this level, but has been rejected roughly 19 times. Thanks to trend line support, we're coming toward a decision point within the next few months. I think there are several good reasons to think we could see a successful breakout soon. Valuation I estimate CAH's forward P/E below 9, and its forward P/S at an amazing 0.09. The stock should have a forward dividend yield of about 3.5%. It's not much of an innovator, but its pace of patent filing has been picking up over the last few years. CAH has been growing earnings at an annual rate of about 1.5%, sales at a rate of over 2%, the dividend at 0.5%, and free cash flow at a rate 4%. So it's a growing company with lots of free cash flow and a very attractive PEG ratio. I estimate that CAH has about 17% upside to its median price multiple of the last 4 years, so the stock looks undervalued here. Sentiment S&P Global Market Intelligence gives CAH an average rating of 86.75/100. It gets a better-than-average ESG score as well. The average analyst score, according to Thompson-Reuters Starmine, is 9/10. This score has recently increased by several points. Open interest from option traders is in bullish territory, at 0.9. Technicals are bullish, and CAH has 17.5% upside to the average analyst price target. Overall, sentiment looks quite positive for CAH.
NYSE:CAHLong
by ChristopherCarrollSmith
3
APHA Day Trade IdeaAPHA (Aphria, Inc.) is rebounding up from a support line on the year to date rising fibonacci channel. It is probable that APHA will continue it's upward momentum up to 17.81 for an approximate 13% gain (+/-) upon where it would encounter the yearly 61.8% fibonacci resistance level. If APHA crosses above 17.81, the Point of control (POC) where volume is most concentrated is at 18.75. Crossing this level is less probable but not impossible, as APHA has been known to out perform both in market hours and after hours. I currently have no position in APHA, so this is just my unbiased opinion.
ALong
by khollspati
CLOV - There's absolutely NO SHOT..... right?Alright, so hear me out. NASDAQ:CLOV has this insane, speculative expanding wedge/triangle pattern forming. I mean, there's absolutely NO SHOT this can actually play out. It HAS to be just a coincidence...... right? The featured content is intended to be used for informational purposes only. Everything shared here is my own opinion. It is very important to do your own analysis before making any investment based on your own personal circumstances.
NASDAQ:CLOVLong
by jstrasburger
9
OcugenOcugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. I might've marked this up a few weeks ago. However, here is an updated outlook after hearing some positive news from its camp that was released today. What do you think? Like, Follow, Agree, Disagree! Details in photo! Strike price $12.12
NASDAQ:OCGNLong
by Redimere_91
11
EDIT Genome Editing Long-Term SwingEDIT NASDAQ:EDIT is a genome editing company with treatments being developed for Leber congenital amaurosis**, Usher syndrome, neurological diseases, Sickle cell disease, beta-thalassemia, as well as cancer treatments through NK cells. The leber congenital amaurosis clinical trial is currently the furthest along but still in its earlier stages but has completed dosing all of its patients. The results of that clinical trial will be HUGE. That will set the blueprint for EDIT as a company. The same principles for that EDIT-101 clinical trial are being applied to multiple other medicines and can lay the blueprint for huge medical breakthroughs. ARK believes genome editing is the future of medicine and I agree. This 46% sell off since EDIT’s highs looks to be a strong bounce area. I grabbed a small starter position on Friday last week but will look to add to my position this week and add dips to $50. If we fail $50.48 HVN area I will use that as my stop. Chart: EDIT looks to be in a prime bounce zone right now and I will be looking for it to hold the HVN area ($57-$66) for some consolidation. Daily .618 fib retracement line has served as support multiple times and will want that to hold up this week. Need some volume to being accumulating on EDIT and close back over the $58 lvl.
NASDAQ:EDITLong
by DOpeTrades
1
Flag forming in Gold. $2,200 possible within the yearGold has been consolidating and retracting in volume. It looks coiled to break-out past previous resistance. The 50,100, and 200-day moving averages are on the verge of intersecting and hopefully reversing course in a more bullish direction. Signal to buy should be when shorter-term MA's breakthrough 200-day. RSI, MACD, and Gold spot prices have been declining in unison. RSI signals it is not overbought and MACD is signaling buy which gives this trade some legs and breathing room. On the fundamental side, gold is the most resistant to rust and corrosion, making it the most reliable and durable electrical conductor. It is key for computer and satellite technology. If Starlink is going to become a reality, regardless of whether or not it does so under the umbrella of Tesla or by IPO'ing, they will need a lot of gold to make those satellites low maintenance. Gold is also essential in the production of green technology and it is essential for healthcare and our digital world. I expect spot prices of $2,200 within the year and at least $2,500 by 2022.
TVC:GOLDLong
by EBITDAtiger
3
$CLOV Stick to the PlanTrue longs are staying patient, even with the volatile week we've experienced thus far. $CLOV is attempting to make a presence within the healthcare industry, which is never an easy path. Their mission as a company will be very difficult to pursue, although a very lucrative one if executed adequately. With a Biden Administration advocating health care for all in America, the push from various lawmakers in congress will help aid individuals gain access to companies like Clover, who are offering insurance at very little-to-none premiums, copays, and prescription drug prices. I will be updating this post as I have entered a multi-week swing, which may turn into a long-term hold- depending on confirmation within the price action. GLTA!
NASDAQ:CLOVLong
by ClargyInvesting
1
FMS Technical Analysis 🧙Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NYSE:FMSLong
by trading_as_bus
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
Z
by AlenCiken
$CLOV Bearish Channels Breakout upward Incoming$CLOV was consolidating after a retracement down. After consolidation and approaching the edge of a wedge indicating a big movement. They were unexpectedly the target of a short sellers report which caused the movement to continue downward. With a well articulated rebuttal the doc was able to rally and bounce back up. We appear to be at the bottom of a bearish channel and will likely retrace back up in the near future a short squeeze caused by any positive catalyst will likely break the channel upward allowing us to retrace upward towards the $14 area. With February 19th options expiring I expect the retracement to happen soon after.
NASDAQ:CLOVLong
by iamphatboy
Bottom-fishing for long-term trading.According to Wells Fargo Advisors, "BAX: OMCL Would Be An Excellent Fit ... OMCL would bring better IT integration and an expanded set of hospital relationships as Baxter launches a new infusion pump next year. OMCL might also be able to finally realize its vision of a stronger international business (9% of total revenue) with the help of Baxter’s infrastructure. The pandemic pressured OMCL’s original 13% revenue growth target for 2020 down to a 2% revenue decline. However, management indicated bookings surged so much in Q3 the company was able to reinstate its original 9% bookings growth guidance for 2020 and gave a 2021 revenue outlook of 17% growth (13% organic). So, fundamentals seem solid."
NYSE:BAX
by KhanhC.Hoang